Clinical Trial Update: Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) [Phase 3]

View source ↗

Summary

Phase 3 trial update: Axsome Therapeutics is evaluating solriamfetol's modulation of TAAR-1, dopamine, and norepinephrine for shift-work disorder-related excess…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excessive Sleepiness
• Shift-work Disorder

Drugs mentioned

• Sunosi (solriamfetol)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Excessive Sleepiness, Shift-work Disorder | Phase 3 | Status: RECRUITING